Overview of Eucreas

Property	Description
Active Ingredients	Metformin Hydrochloride, Vildagliptin
Form	Film-coated tablets
Pharmacological Class	Antidiabetic Agents (Biguanide and DPP-4 Inhibitor combination)
Common Use	Improving glycaemic control in Type 2 Diabetes Mellitus
Origin	Synthetic

Defining Eucreas: A Fixed-Dose Oral Antidiabetic

Eucreas is a prescription-only medicine defined as a fixed-dose combination (FDC) product used to manage high blood sugar. It is supplied as film-coated tablets intended for oral administration and is broadly classified as an oral antidiabetic agent. This product is known in some markets by the alternative brand name Galvumet, confirming the unique pairing of active substances. The FDC structure simplifies patient adherence by delivering two necessary compounds in one unit, which is a key differentiating factor from single-ingredient treatments.

Active Composition: Metformin and Vildagliptin Classes

The tablets contain two distinct active pharmaceutical ingredients (APIs): Metformin Hydrochloride and Vildagliptin. These components represent two separate pharmacological classes, providing complementary action for regulating blood glucose. Metformin Hydrochloride is categorized as a Biguanide. Vildagliptin is classified as a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, a class that affects the body's natural hormonal signaling system. The strategic combination of these two agents addresses both the baseline overproduction of glucose and the impaired hormonal response characteristic of Type 2 Diabetes.

General Purpose: Dual Action for Glycaemic Control

The general purpose of this FDC medication is to improve and maintain glycaemic control—helping the body keep blood sugar levels within a safer range—in adult patients. The dual mechanism specifically addresses two main pathways: one component (Metformin) is responsible for limiting the excessive release of sugar by the liver, and the other (Vildagliptin) acts to protect and enhance the body’s own incretin hormones. The medicine is typically prescribed when diet and exercise alone have proven insufficient, or when treatment with a single drug has not achieved optimal results. The overall goal is to establish a more balanced metabolic state as an adjunct to diet and exercise modifications.

What side effects are possible with Eucreas ?

Possible Side Effects and Safety Information

The officially documented safety profile of Eucreas, a fixed-dose combination of vildagliptin and metformin, primarily features adverse reactions categorized by frequency and organ system as recognized by regulatory authorities.

Frequency-Classified Adverse Reactions

The most commonly listed adverse events are generally gastrointestinal disorders associated with the metformin component, such as diarrhoea, nausea, vomiting, abdominal pain, and loss of appetite (anorexia). These are often classified as very common or common in official documents. Other common reactions include tremor, dizziness, metallic taste, and hypoglycaemia (low blood glucose) when used with certain other medications.

Less frequently reported events (uncommon) include constipation, peripheral oedema (swelling), and arthralgia (joint pain). Events classified as very rare include serious metabolic complications and skin reactions.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights the risk of Lactic Acidosis, a very rare but severe metabolic complication primarily linked to the accumulation of metformin. This risk is greatly increased in individuals with severely impaired kidney function. Acute Pancreatitis is also a serious adverse reaction reported in post-marketing experience associated with vildagliptin.

Safety constraints and contraindications are explicitly detailed:

Renal and Hepatic Impairment: The medicine is contraindicated in patients with severely reduced kidney function (GFR < 30 ml/min) and those with hepatic impairment (liver disease).
Acute Conditions: Temporary discontinuation is required during conditions associated with severe illness, dehydration, or procedures using iodinated contrast agents (for imaging) due to the risk of Lactic Acidosis.

Official documents mandate monitoring of kidney and liver function both before and during treatment, particularly in older adults, to manage safety risks.

Overdose and Emergency Response

The official overdose information for Eucreas is defined by two key domains: the severe risk of Lactic Acidosis and the need for immediate, regulated emergency action. The Lactic Acidosis outcome is a documented, life-threatening metabolic emergency associated with the Metformin component.

Overdose Scope	Official Regulatory Description
Documented Manifestations	Symptoms may include non-specific signs such as severe malaise, myalgias (muscle pain), abdominal distress, and increasing somnolence. More marked acidosis may present with respiratory distress (acidotic dyspnoea), hypothermia, or hypotension. The Vildagliptin component overdose may manifest as hypoglycaemia.
Population-Specific Note	The risk of Lactic Acidosis is officially noted to be significantly increased in the elderly and in patients with impaired renal function due to reduced drug clearance.
Immediate Regulatory Action	The medicine must be stopped immediately. Any suspicion of Lactic Acidosis constitutes a medical emergency and requires the patient to seek immediate medical attention for hospital treatment.

Management is defined as strictly symptomatic and supportive, and no specific antidote is known for Metformin. Prompt hemodialysis is the recommended procedural step for removing the accumulated drug and correcting the severe acidosis, as described in official prescribing information.

Therapeutic Uses of Eucreas

Eucreas: Main Uses and Benefits for Type 2 Diabetes

Eucreas is a combination medicine containing vildagliptin and metformin hydrochloride, generally applied in the management of Type 2 diabetes mellitus in adults, often alongside diet and exercise. Its use is focused on managing symptoms related to systemic imbalance, such as those associated with fluctuating blood glucose levels.

The medicine is used for managing symptoms associated with acute or episodic changes in blood sugar levels, which may become more disruptive during periods of poor glycemic control. It is commonly used in contexts involving heightened systemic burden, where supportive symptom management is appropriate. The active substances support general well-being during symptomatic phases by assisting with the maintenance of functional stability.

This medication may assist with conditions characterized by periods of heightened symptoms and involving episodic or fluctuating manifestations. This supportive relief contributes to easing the overall symptom load and helps individuals manage more steadily through glucose fluctuations. It is applied across domains where additional symptomatic support is needed, particularly when short-term symptomatic assistance is required to regain stability.

“This medication supports general well-being during symptomatic phases.”

Quick Fact: Relief for Systemic Imbalance

Regulatory References

European Medicines Agency overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Eucreas?

Eligibility for Eucreas is defined by regulatory bodies and is strictly limited to adult patients (ge 18 years old) with Type 2 Diabetes Mellitus. This medication is typically prescribed when blood sugar control is insufficient with metformin alone, or as part of a triple combination regimen with a sulfonylurea or insulin.

Official Contraindications and Restrictions

Regulatory agencies have established absolute non-eligibility rules (contraindications) and population-specific restrictions for this combination medicine, primarily related to the patient’s underlying organ function and age.

Absolute Prohibitions (Contraindications)

Category	Non-Eligible Condition
Organ Failure	Severe renal failure (GFR < 30 mL/min/1.73 m^2) or severe hepatic impairment (liver dysfunction).
Metabolic State	Diabetic ketoacidosis, diabetic pre-coma, or conditions causing tissue hypoxia (e.g., recent heart attack, shock).
Physiological Status	Known hypersensitivity to the active ingredients (vildagliptin, metformin) or excipients.
Reproductive	Breastfeeding women.

Populations with Limited or Restricted Use

Age: Use is not recommended in children, adolescents (< 18 years), or in patients older than 75 years due to insufficient data on safety and effectiveness.
Pregnancy: Not recommended during pregnancy.
Acute Illness: The medicine must be temporarily discontinued during acute conditions (e.g., severe infection, dehydration) or when undergoing a radiological study involving an iodinated contrast agent.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Eucreas, a fixed-dose combination of Vildagliptin and Metformin, is primarily structured around the two individual active substances, as Vildagliptin exhibits a low potential for interaction because it neither inhibits nor induces CYP450 enzymes. Metformin’s interactions are largely governed by the Organic Cation Transporter ( OCT) system, which manages its elimination.

Documented Interaction Patterns

Category	Documented Outcome (Regulatory Statement)
Timing Restriction	Iodinated contrast agents require mandatory temporary discontinuation of Eucreas prior to or at the time of administration, and it must not be restarted for at least 48 hours until stable renal function is confirmed.
Exposure Modification	Inhibitors of OCT2 (e.g., Cimetidine, Ranolazine) decrease the renal clearance of Metformin, which leads to an increased plasma concentration and raises the documented risk of systemic exposure.
Pharmacodynamic Risk	Co-administration with Sulfonylureas or Insulin results in an additive blood glucose-lowering effect, leading to an officially documented increased risk of hypoglycaemia.
Substance Restriction	Acute or excessive alcohol consumption is associated with an officially documented increased risk of lactic acidosis, especially in individuals with hepatic impairment.

Interaction-Related Context

Interaction risks are also heightened in populations with hepatic impairment, renal impairment, or other acute conditions that may acutely alter renal function. Additionally, co-administration with ACE inhibitors has been associated with an increased risk of angioedema, while the efficacy of the medicine may be reduced by substances with intrinsic hyperglycaemic activity (e.g., glucocorticoids, sympathomimetics).

Mechanism of Action

Vildagliptin's mechanism involves inhibiting the Dipeptidyl Peptidase-4 (DPP-4) enzyme. This inhibition prevents the rapid breakdown of the incretin hormones (GLP-1 and GIP), sustaining their active levels. The resulting elevated incretin activity enhances glucose-dependent insulin release from the pancreatic beta cells and modulates the suppression of the counter-regulatory hormone, glucagon. This action modulates the body's physiological response to circulating glucose, especially following food intake. The complementary metformin component primarily reduces the amount of glucose the liver synthesizes and releases. This effect is associated with the activation of AMP-activated protein kinase (AMPK), which consequently decreases the metabolic pathway of gluconeogenesis. By reducing the liver's glucose output and simultaneously increasing the utilization capacity of peripheral tissues for glucose, this dual mechanism results in a sustained shift toward a reduced baseline of circulating glucose.

Dosage and Administration Information

How to Use Eucreas: Official Administration Guidelines

Eucreas is an oral medication supplied as film-coated tablets that must be administered according to specific protocols governing its fixed-dose composition.

Administration and Dosing Schedule

The medicine is prescribed for twice daily administration, with the total daily dose divided into two portions, typically taken once in the morning and once in the evening. Each tablet must be taken with or immediately after food; this procedural instruction is necessary to enhance proper tolerability, particularly concerning the metformin component. The tablets must be swallowed whole with water and must not be chewed.

The maximum established daily dose is restricted to 100 mg of Vildagliptin and 2,000 mg of Metformin Hydrochloride, a ceiling based on clinical regulatory data. If a scheduled dose is missed, a compensatory double dose must not be taken.

Population-Specific and Procedural Requirements

The official protocol dictates usage constraints for specific patient populations. The medicine is not recommended for use in children and adolescents, and its use is strictly avoided in patients with hepatic impairment. For older adults, the label requires regular monitoring of renal function. Furthermore, dosing must be precisely adjusted based on the patient's estimated Glomerular Filtration Rate (eGFR) when mild to moderate renal impairment is present, confirming strict dose limits for eGFR ranges between 30 mL/min and 59 mL/min.

A critical procedural step requires the medicine's temporary suspension when a patient undergoes diagnostic imaging involving iodinated contrast agents. In this context, the medicine is to be discontinued at the time of the procedure and should only be restarted after a minimum of 48 hours, subject to a stable re-evaluation of renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eucreas

Evidence for Use in Type 2 Diabetes Mellitus

Research has primarily explored the vildagliptin/metformin combination in adults diagnosed with Type 2 Diabetes Mellitus, a condition where symptoms may vary in intensity. Studies were evaluated in research examining systemic or functional imbalance. Many included short-term randomized controlled trials (RCTs) monitoring physiological strain related to blood glucose levels, with outcomes related to systemic or functional imbalance, such as HbA1 c.

Findings describe patterns observed in studies where patients receiving the vildagliptin/metformin combination reported differences in blood sugar measurements compared to placebo groups during the short study period. This research provides insight into short-term changes in these key markers. The certainty remains low regarding the full picture of outcomes, as follow-up durations were often limited, and data are still emerging.

Evidence for Use in Combination with Other Medications

Research examined the combination when used alongside other specific medications for diabetes, such as sulfonylureas or insulin. These studies explored scenarios involving periods of heightened symptoms where blood sugar was not adequately managed by two medications. Studies monitored changes, and findings indicate patterns where the addition of the combination was associated with measured differences in HbA1 c levels in some observed populations.

Long-term effects are not fully established when this combination is used as part of a three-drug regimen. Subgroup findings are uncertain, and evidence quality varies across the research conducted.

Long-Term Studies and Follow-Up

Long-term studies focus on outcomes reflecting daily functioning and monitoring physiological strain over many months or years. Studies monitored whether the observed patterns in blood sugar levels persisted for a certain duration, but certainty remains low for outcomes over several years. There is limited information, especially concerning the durability of response and any potential changes in outcomes related to cardiovascular health.

What is Still Uncertain About Eucreas

One uncertainty is the scope of long-term effects, as follow-up durations were limited in initial trials. We have limited information for long-term outcomes related to sustained functional benefit or safety. Data for certain groups, such as children and adolescents, remain extremely limited or unavailable. Additionally, comparative evidence is lacking against all other treatment options for Type 2 Diabetes Mellitus.

Key Studies & References

Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus - European Review for Medical and Pharmacological Sciences (Meta-analysis)

Frequently Asked Questions (FAQ)

Common questions about Eucreas (FAQ)

Q: How is Eucreas different from taking Metformin and Vildagliptin as separate tablets?

A: Eucreas is a fixed-dose combination tablet, which means it contains both active ingredients in one pill. Official regulatory studies have confirmed that the substances are absorbed in the body in the same way as when they are taken separately (bioequivalent). The primary difference is that the single tablet structure is often used to make treatment regimens simpler and potentially easier for patients to follow.

Q: Is Eucreas considered a first-line treatment for Type 2 diabetes?

A: According to official therapeutic indications, Eucreas is typically not prescribed as a first-line treatment. It is generally indicated for adults with Type 2 diabetes whose blood sugar is not adequately controlled when they are taking metformin alone. It may also be prescribed for patients already using the two active ingredients as separate tablets.

Q: What is the difference between Eucreas 50/850 mg and Eucreas 50/1000 mg?

A: The official product information shows that both tablet strengths contain the same amount of Vildagliptin (50 mg). The difference lies in the dosage of the other active ingredient, Metformin. The specific strength is based on the patient's prescribed treatment plan.

Q: Is there a risk of low blood sugar (hypoglycemia) when taking Eucreas by itself?

A: Regulatory documents indicate that when one of the active components (Vildagliptin) is used as a single therapy, the risk of hypoglycemia (low blood sugar) is classified as uncommon. The risk is officially documented as being higher and more common when Eucreas is used in combination with certain other diabetes medications, such as a sulfonylurea or insulin.

Q: Can Eucreas be used along with other diabetes medications like sulfonylureas or insulin?

A: Yes, official indications state that Eucreas can be used in combination with a sulfonylurea or insulin (with or without metformin). Official information notes that when used in these combinations, the risk of low blood sugar is increased and monitoring is generally advised.

Q: Does Eucreas cause weight gain, weight loss, or is it considered weight-neutral?

A: Based on clinical data reviewed by regulatory bodies, the vildagliptin/metformin combination appears to have a minimal effect on body weight for most patients. Studies generally show that it is associated with little to no change in weight when used in combination with other treatments.

Q: Are headaches a common side effect reported by people taking Eucreas?

A: Yes, regulatory documentation classifies headache as a common side effect reported by individuals taking Eucreas. This is listed alongside other common effects like tremor and dizziness.

Q: Is Eucreas safe for people who have certain pre-existing heart conditions?

A: The medicine is contraindicated and must not be used in individuals experiencing acute conditions that cause a lack of oxygen to the body's tissues (tissue hypoxia). This includes serious events like a recent heart attack or shock. A doctor must determine the suitability of this medicine based on a patient's full medical history.

Q: Is there any evidence that Eucreas affects the risk of cardiovascular events?

A: Official regulatory reviews of the vildagliptin component have included studies focused on cardiovascular safety. These trials generally found that no increased cardiovascular risk was identified. However, the regulatory information also notes that certainty regarding very long-term outcomes remains limited.

Q: Why might a doctor switch a patient from separate vildagliptin and metformin tablets to Eucreas?

A: The official indication notes that Eucreas can be prescribed to patients who are already stabilized on the two components taken as separate tablets. Switching to the fixed-dose combination can help simplify the treatment regimen and potentially improve patient adherence by reducing the number of pills needed.

Q: Does taking Eucreas increase the risk of a Vitamin B12 deficiency over time?

A: The metformin component of Eucreas is associated with a potential risk of decreased serum Vitamin B12 levels, especially when the medicine is used long-term. The risk may lead to a doctor determining that monitoring of Vitamin B12 levels is appropriate for the patient.

Q: How often should liver enzymes be checked when a person is on Eucreas?

A: According to official safety instructions, liver function tests must be performed prior to the start of treatment with Eucreas. They are then typically required every three months during the first year of treatment, with periodic checks thereafter.

Q: What should be done if a tablet of Eucreas is missed?

A: If a regular dose is missed, regulatory patient information advises that it should simply be skipped. The next scheduled dose should be taken at the usual time. Patients are strictly advised never to take a double dose to try and make up for the one they missed.

Q: Is Eucreas safe for women who are planning a pregnancy or are currently breastfeeding?

A: Official guidance states that Eucreas is not recommended for use during pregnancy, and it is contraindicated (absolutely prohibited) for women who are breastfeeding. Women who are actively planning to become pregnant should consult with a doctor to review the potential risks and best treatment options.

Q: Can Eucreas be used to treat Type 1 diabetes?

A: No. The official product information specifies that Eucreas is indicated only for the management of Type 2 diabetes mellitus. It is not approved for use in patients with Type 1 diabetes or for treating diabetic ketoacidosis.

Q: Can Eucreas affect a person's ability to drive or operate machinery?

A: Official labeling states that if dizziness occurs, the patient's ability to drive or operate machinery may be impaired, and caution is necessary. Dizziness is listed as a common side effect of the medicine.

Q: Has Eucreas been studied in children or adolescents?

A: Official guidance states that the use of Eucreas is not recommended in children and adolescents under the age of 18. This restriction is due to the lack of sufficient regulatory data demonstrating the safety and effectiveness of the medicine in this population.

Q: What symptoms should prompt a patient to immediately seek medical attention while on Eucreas?

A: If a patient develops signs of a serious adverse reaction, such as symptoms of lactic acidosis (e.g., unusual muscle pain, difficulty breathing) or acute pancreatitis (e.g., persistent, severe abdominal pain), immediate action is required. If these serious symptoms occur, official guidance is to immediately seek medical attention for evaluation.

How should Eucreas be stored and disposed of?

Storage and Disposal Requirements

Official regulatory information defines specific conditions for storing and disposing of Eucreas to ensure product stability and safety.

Storage Component	Requirement
Temperature Limit	Do not store above 30^circC.
Moisture Protection	Store in the original package (blister) in order to protect from moisture.
Child Safety	Keep this medicine out of the sight and reach of children.
Expiration	Do not use this medicine after the expiry date stated on the blister and carton.

For disposal, the medicine must not be thrown away via wastewater or household waste. Individuals should ask a pharmacist for instructions on how to properly dispose of medicines no longer needed. Adhering to these guidelines helps protect the environment and maintain drug integrity.

Eucreas